Siemens Healthineers continues to be a high-conviction 'BUY', with its price target reaffirmed at €48 per share. This positive outlook is primarily fueled by the robust performance of its Imaging and Precision Therapy divisions. While the company's diagnostics segment faces ongoing structural impairments, the core growth is effectively driven by its ex-China Imaging operations and the Varian business. The company's strong third-quarter 2026 results further validate this optimistic stance, showcasing solid order momentum with a 1.3x book-to-bill ratio and impressive margin strength at 19.1%, alongside an upward revision of EPS guidance to €2.45, partly attributed to tariff refunds.
A critical adjustment to the investment thesis involves excluding a significant recovery in the Chinese market from the base case. This strategic shift acknowledges the volatility and non-essential nature of the Chinese market in the current assessment, allowing for a more focused projection on other growth avenues. Despite this conservative approach, Siemens Healthineers is poised for substantial annualized upside, potentially exceeding 15%, even with a modest 3-5% ex-China EPS growth. This resilience is underpinned by enduring secular trends in healthcare and a stable, deeply embedded customer base that ensures consistent demand for its advanced medical technologies.
The sustained 'BUY' rating and price target reflect the company's strong fundamentals and strategic positioning in a growing global healthcare market. Siemens Healthineers exemplifies how innovation and a clear market strategy can drive success, offering investors a compelling opportunity in the healthcare sector. The company's commitment to advancing medical technology and its ability to adapt to changing market dynamics highlight a robust investment case, promising continued value creation for shareholders.
